Summer Sale Get Elite for just $199.50

00

Days

00

Hours

00

Mins

00

Sec

Claim Now

Zai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?

By Zacks Equity Research | July 23, 2025, 9:57 AM

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Zai Lab Limited Unsponsored ADR (ZLAB): Free Stock Analysis Report

Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Vertex Pharmaceuticals Inc

Zai Lab Limited ADR

Latest News

Jul-02	CRSP, VRTX Stocks Surge As FDA Clears Casgevy For Children Ages 2 And Up VRTX +6.03% Stocktwits
Jul-01	Vertex Announces US FDA Approval for Expanded Use of CASGEVY for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia VRTX Business Wire
Jul-01	BridgeBio gets funding for drug launch; United buys into cell therapy VRTX BioPharma Dive
Jun-16	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas ZLAB Business Wire
Jun-16	Vertex Pharmaceuticals CFOs case for thinking like a portfolio manager VRTX CFO.com
Jun-11	Vertex Presents New Data on CASGEVY, Including First European Presentation of Data in Children Ages 5-11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions VRTX Business Wire
Jun-08	Zai Lab Receives China NMPA Approval of TIVDAK (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer ZLAB Business Wire
Jun-08	BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors VRTX TMX Newsfile
Jun-05	Vertex Presents New Data on ALYFTREK at European Cystic Fibrosis Conference VRTX Business Wire
Jun-03	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 VRTX Business Wire
Jun-01	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy VRTX Business Wire
May-28	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside VRTX Investing.com
May-28	Vertexs Jounavx made history, but still left a void in the pain space VRTX Pharma Voice
May-28	Vertexs Journavx made history, but left a void in the pain space VRTX Pharma Voice
May-21	Zai Lab Announces Changes to Senior Leadership Team ZLAB Business Wire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)